<DOC>
	<DOCNO>NCT01347970</DOCNO>
	<brief_summary>This randomized phase II trial study side effect well low-dose carvedilol work prevent congestive heart failure ( CHF ) young cancer survivor expose high dose anthracyclines management childhood cancer . Carvedilol may help low risk cardiovascular complication</brief_summary>
	<brief_title>Pharmacologic Reversal Ventricular Remodeling Childhood Cancer Survivors Risk Congestive Heart Failure ( PREVENT-CHF ) : A Phase IIB Randomized Placebo-Controlled Trial</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine impact two-year course low-dose carvedilol surrogate echocardiographic index CHF risk , include : left ventricular ( LV ) posterior wall thickness-dimension ratio ( LV T-D ) ; LV systolic diastolic function , afterload ; natriuretic peptide , troponins , galactin-3 . II . To establish safety tolerability two-year course low-dose carvedilol , assess objective measure ( hepatic function ) patient report outcomes . III . To examine modify effect demographic , clinical , molecular characteristic risk : benefit ratio two-year carvedilol intervention . IV . As exploratory goal , examine relationship carvedilol clinical measure efficacy prevention CHF . SECONDARY OBJECTIVES : I . Evaluate long-term efficacy carvedilol prevent cardiomyopathy and/or heart failure high-risk childhood cancer survivor . OUTLINE : This dose-escalation study . Patients randomize 1 2 treatment arm . ARM I : Patients receive low-dose carvedilol orally ( PO ) ( QD ) twice daily ( BID ) 24 month . ARM II : Patients receive placebo PO QD BID 24 month . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Cancer diagnosis prior 22 year age , irrespective current age Lifetime cumulative anthracycline dose : &gt; = 300 mg/m^2 without protection dexrazoxane ( Zinecard ) therapy Time completion cancer treatment study entry : &gt; = 2 year Receiving treatment cardiomyopathy congestive heart failure Resting ejection fraction &lt; 50 % fractional shortening &lt; 25 % Uncorrected primary obstructive severe regurgitative valvular disease , nondilated ( restrictive ) hypertrophic cardiomyopathy , significant systemic ventricular outflow obstruction Low rest systolic blood pressure : &lt; 90 mm hemoglobin ( Hg ) Bradycardia : heart rate &lt; 50 beat per minute ( BPM ) Sustained symptomatic ventricular dysrhythmias uncontrolled drug therapy implantable device ; significant conduction defect ( i.e . : second third degree atrioventricular block sick sinus syndrome ) History current clinical evidence moderate tosevere obstructive pulmonary disease reactive airway disease ( i.e . : asthma ) require therapy Significant hepatic ( serum aspartate aminotransferase [ AST ] and/or alanine aminotransferase [ ALT ] &gt; 3 time upper limit normal institutional normal ) , gastrointestinal , biliary disorder could impair absorption , metabolism , excretion orally administer medication Endocrine disorder primary aldosteronism , pheochromocytoma , hyper hypothyroidism control medication , insulin dependent diabetes mellitus Females child bear potential pregnant , lactating , sexually active take adequate contraceptive precaution ( i.e . : intrauterine device [ IUD ] oral contraceptive 3 month prior entry study ) History drug sensitivity allergic reaction alpha betablockers Anemia ( hematocrit &lt; 28 % ) Use investigational drug beta adrenergic blocker , include metoprolol , sotalol , within 30 day randomization Use select cytochrome P450 2D6 ( CYP2D6 ) inhibitor medication Inability swallow pill Unwillingness inability cooperate , , parent guardian minor , give consent , child give assent , condition sufficient severity impair cooperation study Use blood pressure lower medication treatment hypertension , within 30 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>childhood cancer survivor</keyword>
	<keyword>CHF</keyword>
	<keyword>risk congestive heart failure</keyword>
</DOC>